Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- Resource Type
- Article
- Source
- The Lancet; December-January 2018, Vol. 392 Issue: 10165 p2705-2717, 13p
- Subject
- Language
- ISSN
- 01406736; 1474547X